

### Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

#### Listing of Claims

Claim 1-3 (canceled)

<sup>1</sup>  
Claim ~~4~~ (previously presented) The antibody Mab 1F1, secreted by the hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the number I-2038.

Claim 5-6 (canceled)

<sup>4</sup>  
Claim ~~7~~ (currently amended) Pharmaceutical composition comprising a therapeutically effective quantity of the monoclonal antibodies according to claim [[13 or]] 14, the said quantity being therapeutically effective for inducing apoptosis in tumor cells.

<sup>5</sup>  
Claim ~~8~~ (currently amended) Hybridoma line capable of secreting monoclonal antibodies according to claim [[13 or]] 14.

<sup>2</sup>  
Claim ~~9~~ (original) Hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the deposit number I-2038.

Claim 10 -13 (canceled)

<sup>3</sup>  
Claim ~~14~~ (previously presented) Monoclonal antibody directed against the protein of SEQ ID NO:1 and capable of inducing apoptosis in various types of tumor cells, wherein the antibody recognizes an epitope between amino acids 22-34 of SEQ ID NO:1.